Advertisement
  • Loading metrics

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

  • Molly R. Perkins,

    Affiliations Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America, MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

  • Caroline Ryschkewitsch,

    Affiliation Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America

  • Julia C. Liebner,

    Affiliation Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America

  • Maria Chiara G. Monaco,

    Affiliation Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America

  • Danielle Himelfarb,

    Affiliation Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America

  • Sara Ireland,

    Affiliation Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  • Annelys Roque,

    Affiliation Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America

  • Heather L. Edward,

    Affiliation Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America

  • Peter N. Jensen,

    Affiliation Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America

  • Gina Remington,

    Affiliation Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  • Thomas Abraham,

    Affiliation Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  • Jaspreet Abraham,

    Affiliation Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  • Benjamin Greenberg,

    Affiliation Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  • Charles Kaufman,

    Affiliation Louisiana Neurologic Consultants. Baton Rouge, Louisiana, United States of America

  • Chris LaGanke,

    Affiliation North Central Neurology, Cullman, Alabama, United States of America

  • Nancy L. Monson,

    Affiliation Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  • Xiaoning Xu,

    Affiliation MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

  • Elliot Frohman,

    Affiliation Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  • Eugene O. Major ,

    majorg@ninds.nih.gov (EOM); ddouek@mail.nih.gov (DCD)

    Affiliation Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America

  •  [ ... ],
  • Daniel C. Douek

    majorg@ninds.nih.gov (EOM); ddouek@mail.nih.gov (DCD)

    Affiliation Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America

  • [ view all ]
  • [ view less ]

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

  • Molly R. Perkins, 
  • Caroline Ryschkewitsch, 
  • Julia C. Liebner, 
  • Maria Chiara G. Monaco, 
  • Danielle Himelfarb, 
  • Sara Ireland, 
  • Annelys Roque, 
  • Heather L. Edward, 
  • Peter N. Jensen, 
  • Gina Remington
PLOS
x

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.